Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07012148 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Optimizing Therapy in Epilepsy Using Seizure Forecasts Via EEG and Wearables

Study acronym: FORESITE
StatusRecruiting
PhaseEarly Phase 1
Started2026-01-20
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoints added 2 → 4 primary endpoints
See other at-risk trials from Mayo Clinic

Amendment history

2026-09-25
critical
Phase changed: not applicable → Early Phase 1
Primary endpoint(s) modified2 to 4 entries
WasSafety and Adverse Events, Surgical and Device related adverse events
NowFeasibility outcome, Preseizure alert feasibility, Safety and Adverse Events, Safety- cardiorespiratory events
Interventions modified
2026-03-18
minor
Study Status v6
Re-verified, no change to tracked fields
2026-01-19
minor
Study Status v5
Start date2025-12→2026-01-20
2025-12-16
minor
Study Status, Oversight v4
Start date2025-10→2025-12
2025-10-07
minor
Study Status v3
Start date2025-08→2025-10
Show 2 earlier versions
2025-08-01
notable
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start date2025-07→2025-08
Study sitesdetails revised at 1 of 1 site
2025-06-18
minor
Study Status, Contacts/Locations, References v1
Publications+1,152 characters
Pal Attia T, Viana PF, Nasseri M, Duun-Henriksen J, Biondi A, Winston JS, P Martins I, Nurse ES, Dumpelmann M, Worrell GA, Schulze-Bonhage A, Freestone DR, Kjaer TW, Brinkmann BH, Richardson MP. Seizure forecasting using minimally invasive, ultra-long-term subcutaneous EEG: Generalizable cross-patie [...]
2025-06-09
minor
Original filing
1,015 trials monitored
See 115 trials at risk
723 trials monitored
See 41 trials at risk
Mayo Clinic is conducting a research study to test a new approach to managing seizures in people with epilepsy whose seizures have not been fully controlled with regular medications. The study uses a small sensor placed just under the skin (not inside the brain) that continuously records electrical brain activity. This information is used to train a personalized computer algorithm that learns your individual seizure patterns and forecasts when a seizure is more likely to occur. If you are eligible and choose to participate, you would receive advance warning of elevated seizure risk, allowing you to take a fast-acting medication before a seizure happens. This medication would be in addition to the regular medicines prescribed by your doctor. The goal of the study is to understand whether this kind of forecasting system is safe, comfortable to live with, and capable of helping people gain more control over their seizures with a minimum amount of additional medication. Participation involves a minor surgical procedure to implant a small electrode under the skin above your ear that records your brain's electrical signals continuously over time. You would also wear a smart watch during the study. For the first six months, the system collects data to personalize your seizure forecast model and would not give you an alert. In the second six months, we would calculate your daily seizure risk and you would receive alerts on days when your risk is elevated. On these higher seizure risk days you would take a prescribed fast-acting nasal spray medication. The study is open to adults who continue to have 2 or more seizures per month in spite of having tried at least two antiseizure medications in the past, and whose seizures have shown involvement of the temporal lobe. All study-related procedures, devices, and study medication are provided at no cost to participants. Participants receive financial compensation for their time, and travel expenses to and from Mayo Clinic Rochester are reimbursed for anyone traveling more than 100 miles. If you are interested in learning more, please contact our research coordinator by email at Laivell.Jeffrey@mayo.edu.
Trial Details
NCT Number NCT07012148
Lead Sponsor Mayo Clinic
Collaborators: National Institute of Neurological Disorders and Stroke (NINDS)
Conditions Focal Epilepsy, Generalized Seizure, Drug Refractory Epilepsy
Enrollment 12 participants
Start Date 2026-01-20
Primary Completion 2028-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-09-25